![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1800988
ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ ½ÃÀå º¸°í¼ : Á¦Ç°º°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)Polymerase Chain Reaction Market Report by Product, End User, and Region 2025-2033 |
¼¼°èÀÇ ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 82¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2033³â±îÁö 144¾ï ´Þ·¯¿¡ ´ÞÇϸç, 2025-2033³âÀÇ ¼ºÀå·ü(CAGR)Àº 6.18%¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù.
ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ(PCR)Àº DNA ºÎ¹®ÀÇ º¹¼öÀÇ »çº»À» »ý¼ºÇÏ´Â µ¥ »ç¿ëµÇ´Â ºÐÀÚÁø´Ü ±â¼úÀÔ´Ï´Ù. PCR Àåºñ´Â »çÀü ÇÁ·Î±×·¡¹ÖµÈ ÀÚµ¿ ÀýÂ÷¿¡ µû¶ó ½Ã·áÀÇ ¿Âµµ¸¦ Á¶ÀÛÇÏ°í ¼ö¹é¸¸ °³ÀÇ DNA ¿°±â¼¿ »çº»À» Á¤È®ÇÏ°Ô »ý¼ºÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ÀÌ ±â¼úÀº º´¿ø¼º ¹Ì»ý¹°À» ½Äº°ÇÏ°í ¹è¾çÇÏ¿© °áÇÙ, ÈÄõ¼º¸é¿ª°áÇÌÁõÈıº(AIDS), °¨¿°¼º Áúȯ, ¶óÀÓº´ °ËÃâ¿¡ µµ¿òÀÌ µË´Ï´Ù. µû¶ó¼ À¯ÀüÇÐ, »ý¸í°øÇÐ, ºÐÀÚ»ý¹°ÇÐ, ½Å¾à°³¹ß, ÀÓ»óÁø´Ü µî ´Ù¾çÇÑ »ý¸í°úÇÐ °ü·Ã ºÐ¾ß¿¡ Æø³Ð°Ô Àû¿ëµÇ°í ÀÖ½À´Ï´Ù.
´Ù¾çÇÑ °¨¿°¼º Áúȯ ¹× À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ ¸¸¼ºÁúȯ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸°¡ Àü ¼¼°è¿¡¼ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. Äڷγª¹ÙÀÌ·¯½º(COVID-19)ÀÇ ´ëÀ¯ÇàÀº Á¤È®ÇÑ Áø´Ü°ú °¨¿°ÀÇ Á¶±â ¹ß°ßÀ» À§ÇÑ PCR ±â¼úÀÇ º¸±ÞÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. PCR Àåºñ´Â ¶ÇÇÑ ¿À¿°ÀÇ À§Çè°ú Àüü °øÁ¤¿¡¼ ÀÎÀ§ÀûÀÎ ½Ç¼öÀÇ °¡´É¼ºÀ» ÃÖ¼ÒÈÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.
¸ÂÃãÇü ÀÇ·á¿Í Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡µµ ½ÃÀå Àü¸ÁÀ» ¹à°Ô Çϰí ÀÖ½À´Ï´Ù. À̵é ÀǾàǰÀº PCR ±â¼úÀ» ÅëÇØ ½Äº°µÇ°í °³¹ßµÇ´Â ¸ÂÃãÇü Ä¡·áÁ¦¸¦ Á¦°øÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ ÀÓ»ó Áø´Ü ºÐ¾ß¿¡¼ÀÇ »ç¿ë Áõ°¡, »ý¸í°øÇÐ ºÐ¾ßÀÇ ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿ µîÀÌ ½ÃÀåÀ» ´õ¿í °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
The global polymerase chain reaction market size reached USD 8.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 14.4 Billion by 2033, exhibiting a growth rate (CAGR) of 6.18% during 2025-2033.
Polymerase chain reaction (PCR) refers to a molecular diagnostic technique that is used to make multiple copies of a segment of DNA. A PCR machine is used to manipulate the temperature of the sample in an automatic and pre-programmed procedure to generate millions of copies of DNA sequencing accurately. This technology identifies and cultures disease-causing microorganisms, which aid in the detection of tuberculosis, Acquired Immunodeficiency Syndrome (AIDS), infections and Lyme disease. Owing to this, it finds extensive applications across various life science-related fields, such as genetics, biotechnology, molecular biology, drug discovery and clinical diagnostics.
The increasing prevalence of various infectious diseases and genetic disorders is one of the key factors driving the growth of the market. The rising geriatric population across the globe, which is more prone to chronic medical ailments, is also driving the industry growth. The outbreak of the coronavirus disease (COVID-19) pandemic has further led to the widespread adoption of PCR technologies for accurate diagnosis and early detection of infections. PCR devices also aid in minimizing the risks of contamination and the chances of human errors in the entire process.
The increasing demand for personalized and precision medicines is also creating a positive outlook for the market. These medicines aim to provide tailor-made therapies, which are identified and developed using PCR technologies. Other factors, including the increasing application in clinical diagnostics, along with extensive research and development (R&D) activities in the field of biotechnology, are expected to drive the market further.
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies Inc., BD (Becton, Dickinson and Company), BioMerieux (Institut Merieux SA), Bio-RAD Laboratories Inc., F. Hoffmann-La Roche AG, Fluidigm Corporation, Merck KGaA, Perkinelmer Inc., Promega Corporation, Takara Bio Inc. and Thermo Fisher Scientific Inc.